GlycoMimetics Announces Initial Clinical Data from Phase 1 Portion of Clinical Trial of GMI-1271 in AML Patients
- Encouraging Anti-Leukemic Activity Observed in Patients with Advanced AML; Overall Response Rate of 62% in Initial Cohort of 13 Patients
"We are encouraged by the responses seen so far in patients in this
trial," said
"I am pleased to see the favorable safety profile and early clinical
activity of GMI-1271 in these patients," said
About the Phase 1/2 Clinical Trial
Following the completion of a Phase 1 trial in 2014,
The trial consists of two parts. In the Phase 1 portion, dose escalation
testing is being performed to determine a recommended GMI-1271 dose in
combination with standard chemotherapy. The Phase 1 dose-escalation
portion of the trial is continuing. In the Phase 2 portion,
dose-expansion testing will be conducted to obtain additional safety and
efficacy data in defined sub-populations of AML.
About GMI-1271
In preclinical studies using animal models of AML, the results of which
were presented at meetings of the
In other preclinical studies from which data was presented at the 2015
ASH annual meeting, GMI-1271 was observed to reverse molecular
mechanisms of chemotherapy resistance seen in multiple myeloma.
About AML
AML is a cancer of the blood and bone marrow. AML is the most common
type of acute leukemia in adults and the five-year survival rate is
approximately 24 percent. According to the Surveillance, Epidemiology,
and End Results Program managed by the
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the
clinical development of GMI-1271 and the presentation of clinical data.
Actual results may differ materially from those in these forward-looking
statements. For a further description of the risks associated with these
statements, as well as other risks facing
View source version on businesswire.com: http://www.businesswire.com/news/home/20160302005693/en/
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media